Last reviewed 2026-04-20 · How we verify

Form 3 of AZD5718 tablets

AstraZeneca · Phase 1 active Small molecule Quality 0/100

Form 3 of AZD5718 tablets is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

At a glance

Generic name	Form 3 of AZD5718 tablets
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Form 3 of AZD5718 tablets CI brief — competitive landscape report
Form 3 of AZD5718 tablets updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about Form 3 of AZD5718 tablets

What is Form 3 of AZD5718 tablets?

Form 3 of AZD5718 tablets is a Small molecule drug developed by AstraZeneca.

Who makes Form 3 of AZD5718 tablets?

Form 3 of AZD5718 tablets is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is Form 3 of AZD5718 tablets in?

Form 3 of AZD5718 tablets is in Phase 1.

Manufacturer: AstraZeneca — full pipeline
Compare: Form 3 of AZD5718 tablets vs similar drugs
Pricing: Form 3 of AZD5718 tablets cost, discount & access